Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Frontiers in Endocrinology
|
March 15, 2021
Familial Hyperparathyroidism
Jenny E Blau, William F Simonds
Reviews in Endocrine & Metabolic Disorders
|
August 23, 2015
The PTH-Vitamin D-FGF23 axis
Jenny E Blau, Michael T Collins
Nature Reviews. Nephrology
|
June 8, 2018
Adverse effects of SGLT2 inhibitors on bone health
Jenny E Blau, Simeon I Taylor
BMJ Case Reports
|
January 8, 2021
Acute oesophageal necrosis in multiple endocrine neoplasia type 1: an undescribed complication
Sumona Bhattacharya, Jenny E Blau, Christopher Koh
Reviews in Endocrine & Metabolic Disorders
|
March 4, 2016
Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research
Allison C Sylvetsky, Jenny E Blau, Kristina I Rother
The Lancet. Diabetes & Endocrinology
|
December 20, 2014
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I Taylor, Jenny E Blau, Kristina I Rother
The Journal of Clinical Endocrinology and Metabolism
|
June 19, 2015
SGLT2 Inhibitors May Predispose to Ketoacidosis
Simeon I Taylor, Jenny E Blau, Kristina I Rother
Diabetes/Metabolism Research and Reviews
|
July 25, 2017
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, et al.
Hepatology Communications
|
May 23, 2024
The health care experience of adults with metabolic dysfunction-associated steatohepatitis and influence of PNPLA3: A qualitative study
Jonathan G Stine, Nenad Medic, Billie Pettersson, et al.
The Lancet. Diabetes & Endocrinology
|
October 6, 2019
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Simeon I Taylor, Jenny E Blau, Kristina I Rother, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Frontiers in Endocrinology
|
March 15, 2021
Familial Hyperparathyroidism
Jenny E Blau, William F Simonds
Reviews in Endocrine & Metabolic Disorders
|
August 23, 2015
The PTH-Vitamin D-FGF23 axis
Jenny E Blau, Michael T Collins
Nature Reviews. Nephrology
|
June 8, 2018
Adverse effects of SGLT2 inhibitors on bone health
Jenny E Blau, Simeon I Taylor
BMJ Case Reports
|
January 8, 2021
Acute oesophageal necrosis in multiple endocrine neoplasia type 1: an undescribed complication
Sumona Bhattacharya, Jenny E Blau, Christopher Koh
Reviews in Endocrine & Metabolic Disorders
|
March 4, 2016
Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research
Allison C Sylvetsky, Jenny E Blau, Kristina I Rother
The Lancet. Diabetes & Endocrinology
|
December 20, 2014
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I Taylor, Jenny E Blau, Kristina I Rother
The Journal of Clinical Endocrinology and Metabolism
|
June 19, 2015
SGLT2 Inhibitors May Predispose to Ketoacidosis
Simeon I Taylor, Jenny E Blau, Kristina I Rother
Diabetes/Metabolism Research and Reviews
|
July 25, 2017
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, et al.
Hepatology Communications
|
May 23, 2024
The health care experience of adults with metabolic dysfunction-associated steatohepatitis and influence of PNPLA3: A qualitative study
Jonathan G Stine, Nenad Medic, Billie Pettersson, et al.
The Lancet. Diabetes & Endocrinology
|
October 6, 2019
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Simeon I Taylor, Jenny E Blau, Kristina I Rother, et al.
Page
of 5